



**Supplemental Figure 1.** The gating strategy for donor OT-I cells.



**Supplemental Figure 2.** The kinetics of CD127 and KLRG-1 expression by WT and *Batf3*<sup>-/-</sup> OT-I cells in the MLN. The data are pooled from 3 independent experiments for 9 dpi with n=12 and 2 independent experiments for 15 and 30 dpi with n=7. The data are shown as mean ± SEM.



**Supplemental Figure 3.** The phenotype of WT and *Batf3*<sup>-/-</sup> OT-I cells at 6 dpr. **(A)** CD127 and KLRG-1 expression by WT and *Batf3*<sup>-/-</sup> OT-I cells in the blood. **(B)** CD127 and KLRG-1 expression by WT and *Batf3*<sup>-/-</sup> OT-I cells in the IEL compartment. **(C)** CD103 and CD69 expression by WT and *Batf3*<sup>-/-</sup> OT-I cells in the IEL compartment. The data are pooled from 2 independent experiments with n=7. The data are shown as mean ± SEM.

**Supplemental Table 1. The list of reagents for flow cytometric analysis.**

<b>Reagent</b>	<b>Clone</b>	<b>Vendor</b>
anti-CD8 $\alpha$	53-6.7	BioLegend
anti-TCR $\beta$	H57-597	BioLegend, Invitrogen
anti-TCR V $\alpha$ 2	B20.1	BioLegend, eBioscience
anti-CD45.1	A20	BioLegend, eBioscience
anti-CD45.2	104	BioLegend, eBioscience
anti-CD103	2E7	BioLegend
anti-CD69	H1.2F3	BioLegend
anti- $\alpha$ 4 $\beta$ 7	DATK32	BioLegend, BD Biosciences
anti-CCR9	CW-1.2	BioLegend, eBioscience
anti-IFN $\gamma$	XMG1.2	BioLegend
anti-TNF $\alpha$	MP6-XT22	BioLegend
anti-Granzyme B	GB11	BioLegend
Live/dead dye		Invitrogen
Apotracker <sup>TM</sup> Green		BioLegend
GolgiPlug <sup>TM</sup>		BD Biosciences
Cytofix/Cytoperm <sup>TM</sup>		BD Biosciences
SIINFEKL peptide		Invitrogen